Janpix

Developer of ultra-selective STAT inhibitors designed to treat hematological tumors and glioblastomas. The company’s inhibitors modulates immune cells along with tumour micro-environment in order to facilitate tumour eradication, enabling patients to get proper treatment for cancer.